Focus
Our research and development programs target indications with substantial unmet medical needs: NASH, MPS and oncology.
Innovation
State-of-the-art R&D facilities, with a chemical library of over 240,000 molecules, 60% of which are proprietary.
Partnerships
A royalty bearing partnership in place with Abbvie validating our approach and the potential of our discovery engine.
Inventiva in Numbers
1
Partnership (Abbvie)
2
Innovative Clinical Programmes
90
People in our Scientific Team
13
Patent Families
A Library of
240,000
Compounds
Welcome to Inventiva Pharma
We are a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology.
We have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation.
Leveraging these assets and expertise, we are advancing two clinical candidate, as well as a deep pipeline of earlier stage programs.
Financial Information
Upcoming Events
February 13, 2019
Publication of revenues and cash position
as of December 31, 2018
February 27, 2019
2018 annual financial results
Therapeutic Areas
Non-Alcoholic Steatohepatitis (NASH)
Non-alcoholic steatohepatitis is a severe liver disease which affects 6-8% of adults in western industrialised nations and is on the rise around the globe.
Inventiva is developing lanifibranor for the treatment of NASH to address all the key features of NASH: inflammation, steatosis, ballooning, and importantly fibrosis.
We are currently investigating lanifibranor for the treatment of NASH in NATIVE, a Phase 2b clinical trial, with results expected in the first half of 2020.
Mucopolysaccharidosis
(MPS)
MPS is a group of rare genetic disorders characterized by an excessive accumulation of large sugar chains, known as glycosaminoglycans, or GAGs, in cells.
Inventiva is developing odiparcil, an orally-available small molecule designed to modify how GAGs are synthesized.
In the recently completed iMProveS phase IIa study odiparcil confirmed its favourable safety profile and demonstrated efficacy in adult MPS VI patients, especially in tissues types not reached by standard of care.
Odiparcil
Phase IIa in adult MPSVI patients, completed